Health
Super-backed company develops COVID treatment – Financial Standard
A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by u…
A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by up to 96%.
The product, INNA-051, is being developed by Ena Respiratory, and works by stimulating and boosting the innate immune system. The study found that boosting the immune system this way limits the ability of the COVID-19 virus to infect the animals used in the study.
Ena Respiratory raised $11.7 million from a coalition of instit…
-
General7 hours agoPoliticians asked how to Trump-proof Australia’s fragile economy on Q+A
-
Business20 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Noosa News19 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Business24 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?